Antitubercular drug discovery: the molecular modification as promise tool

Luiz Antonio Dutra1, Thais Regina Ferreira de Melo1, Chung Man Chin1, Jean Leandro dos Santos1

Lapdesf–Laboratório de Pesquisa e Desenvolvimento de Fármacos, Departamento de Fármacos e Medicamentos, Faculdade de Ciências Farmacêuticas – Universidade Estadual Paulista–UNESP, Rodovia Araraquara Jaú Km. 01, 14801-902, Araraquara, SP, Brazil.

Accepted 05 December, 2011

Tuberculosis is a chronic infectious disease caused by etiologic agent Mycobacterium tuberculosis. “It has been reported that rates of incidence is increasing and each year around 8.9-9.9 million new cases are detected”. The current TB therapy presents several problems such as long-term therapy, drug resistance, no-compliance to therapy and few therapeutic sources to treat the disease. The discovery of new drugs safer and more efficient is urgent. The molecular modification is an important tool that allows discovering new compounds that can be win these challenges. In this work, we summarize the main strategies useful to obtain a new anti-tubercular drug.

Keywords: Tuberculosis; antitubercular drugs; new drugs; molecular modification.

INTRODUCTION

Tuberculosis (TB) represents the chronic infectious disease that more kills adults worldwide (Trabulsli and Alterthum, 2005). Between century XVII and XVIII, TB was known as “great white plague” or “tifise. TB was responsible for more than one billion deaths between 1700 and 1900 overcoming any other disease (Daniel et al., 1994).

One of the first studies about TB was performed by Robert Kock (1843-1810) who isolates and cultivates the etiologic agent Mycobacterium tuberculosis (MTB). These results revolutionized the story of Bacteriology and Medicine and this mycobacteria came to be known as Koch’s bacillus. Structurally, MTB presents a complex cell wall composed of long chain fatty acids (with 60-90 carbon atoms known as mycolics acids), glycolipids, peptidoglycan and proteins (Trabulsli and Alterthum, 2005).

TB is transmitted by coughing of a sick individual. The droplets containing expectorated MTB are inhaled and penetrates host lung beginning the infection process (WHO, 2011; Trabulsli and Alterthum, 2005). After MTB infect human lung, an inflammatory process with macrophages activation initiates leading to pro-inflammatory cytokines production such as interleukin IL-6, IL-12, IL-1B, INF-γ (Flynn et al., 2011). The alveolar macrophages infected for MTB produce the Mcl-1 antiapoptotic protein, responsible to interrupt apoptosis of infected macrophages by regulation of mitochondrial membrane, preventing the release of cytochrome c and enzymes responsible for DNA degradation (Sly et al., 2003).

The Immune response acts against MTB allowing other cells to be recruited for infected side to interrupt bacterium growth leading to granuloma formation. The granuloma is an organized structure by immunes cells, formed through antigenic response, which can be observed in latent and active tuberculosis. The granuloma is niche for the bacillus. In this state there is reduction of metabolism regarding immune response activity leading to a quiescence state. This MTB dormant is known as latent TB that unlike of active TB is not characterized as an infectious disease (Russell, 2011; Flynn, 2011).

Immunosuppressive conditions compromise the efficiency of the immune system allowing the reactivation of previously dormant bacilli, leading individual to develop active TB, usually decades after initial infectious. It has been reported that the risk to develop active TB in co-infected individual with HIV is 100 times when compared to only TB infected.
Figure 1. Number of new tuberculosis cases by WHO 2010 and 2011.

Figure 2. Chemical structures of first and second line antitubercular drugs.

individuals (Havlir and Barnes, 1999; Pitchenik et al., 1988). Patients with AIDS are more susceptible to develop opportunistic infections by atypical mycobacteria as *Mycobacterium avium*, *M. kansasii*, *M. fortuitum* and *M. chelonei*. Furthermore, TB induces AIDS development in HIV-positive patients by stimulating cytokines productions and reduction of CD4 + T cells (Trabulsi and Alterthum, 2005).

Nowadays TB represents the second cause of death worldwide. The World Health Organization (WHO) estimates that almost one third of the population is infected with MTB. Furthermore, the number of new TB cases is increasing according WHO reports (Figure 1). Current drug therapy presents several problems such as side effects of drugs, resistance of MTB and co-morbidity. Access to adequate health care in developing countries is another problem for the tuberculosis therapy (Cegielski and McMurray, 2004). The BCG vaccine (Bacilo Calmette-Guérin), an attenuated *Mycobacterium Bovis*, is used by more than a century but it efficiency is questionable (WHO, 2010; WHO, 2011; Haydel, 2010; Smith et al., 2009).

All these problems associated with multidrug-resistance justify the research of new safer and more efficient drugs with reduce adverse side effects allowing adequate compliance by patients.

Multidrug-resistant tuberculosis (MDR-TB)

MTB drug resistance occurs through two different ways: (1) Multidrug-resistant tuberculosis (MDR-TB)-resistance at least two first-line antibiotics, isoniazid and rifampicin; (2) Extensively drug-resistant TB (XDR-TB), is defined as resistant to first and second line drugs (Figure 2) (Raviglione and Smith, 2007).

The resistance mechanism is still a mystery to science, but several biochemical events are required for MTB resistance such as: a) decrease in the intracellular concentration of antibiotics by altering the permeability of outer and inner membranes; b) mutation or modification of the cellular target; c) action of the drug
in another target. All these mechanisms performed by bacillus can lead to MDR-TB and XDR-TB state (Piddock et al., 2006; De Rossi et al., 2006).

Mutations in genes responsible for encoding enzymes recognized as targets, is the main factor to generate resistance to anti-TB drugs of first and second line. The specific interaction of rifampicin with β subunit of RNA polymerase enzyme inhibit transcription caused cell death. Mutations in the rpoB gene, which encodes the chain β enzyme, produce drug resistance by decreasing the interaction of rifampicin with the polymerase (Williams et al., 1998). Isoniazid is a prodrug that requires the katG gene product for its activation; this drug is active after metabolism of MTB catalase-peroxidase C; and d) four genes: a) embA, which encodes the synthase trimidalato enzyme, since it encoded by inhA gene; its resistance involves four genes: a) katG, which encodes the catalase-prefridase enzyme; b) inhA involved in mycolic acid biosynthesis; c) ahpC, that encodes alkyl hydroperoxide reductase C; and d) oxyR, regulator of oxidative stress (Zhang et al., 1992; Banerjee et al., 1994; Trabulsi and Alterthum, 2005). Ethambutol resistance is conferred by mutations in embA, embB e embC genes that encode enzymes involved in arabinano synthesis (Telenti et al., 1997). Pyrazinamide is a prodrug which is effective only against MTB inhibiting fatty acid synthesis. Its resistance occurs by mutations in pncA gene, encoding pirazianamidazes, enzyme that hydrolyzes the drug to make it active (Scorpio et al., 1997). The fluoroquinolones (ciprofloxacin, levofloxacin, moxifloxacin and gatifloxacin) act on the enzymes responsible for the DNA topological conformation. Its resistance is conferred by mutations in the gyrA, gyrB genes, that encode respectively A and B subunits of gyrase DNA (Takiff et al., 1994). Streptomycin acts in the inhibition of protein synthesis, and its resistance is involved with rrs gene, which encodes S12 rRNA, and rpsl, which encodes S12 ribosomal protein. The rpsl also produces resistance to kanamycin and amikacin (Finken et al., 1993; Suzuki et al., 1998). Capreomycin resistance is caused by mutation in the tlyA gene (Maus et al., 2005). The ethioamine is an inhibitor of mycolic acid, responsible for cell wall synthesis and its resistance is due mutations in genes inhA (involved in mycolic acid biosynthesis) and etha, encoding monoxygenase flavin, which its responsible for activating etioamida (Banerjee et al., 1994). Aminosalicylic acid resistance is due mutations in thyA genes, which encodes the synthase trimidalato enzyme, since its regulating intracellular concentrations of folate (Rengarajan et al., 2004).

MOLECULAR MODIFICATION

Molecular modification can enhance pharmacokinetics or pharmacodynamics aspects of the drugs. There are many strategy used by Medicinal Chemistry to design drugs using these strategies such as molecular hybridization, prodrug and bioisosterism. In this review, we suggest the application of this strategy to discovery new antitubercular drugs.

Molecular hybridization

The molecular hybridization is a rational approach to design new prototypes after fusion of pharmacophoric
subunits that can be recognized by two or more biologic receptors (Veigas-Junior et al., 2007). This strategy has been used in TB drug discovery to increase the efficacy and reduce drug resistance. Imrarovský and co-workers combined through molecular hybridization the scaffold of three antitubercular drugs: isoniazid (first line), pyrazinamide (first line) and ciprofloxacin (second line). The compounds had great activity against MTB. The compounds 15 and 16 demonstrated with MIC = 0.78 µg/mL and 0.1 µg/mL respectively (Figure 3) (Imrarovský et al., 2007).

Quinoxaline-1,4-di-N-oxide has been used as scaffold for new hybrids compounds actives against MTB, (Ancizu et al., 2010). Recently, Torres and co-workers (2011) reported the antitubercular activity from the new quinoxaline-1,4-di-N-oxide derivatives (17) obtained by molecular hybridization with the first line drug, isoniazid. The authors demonstrated that halogens in position 7 increase the antitubercular activity. The compounds with chlorine (18) and fluorine (19) demonstrated IC<sub>50</sub> respectively 1.04 µg/mL and 0.58 µg/mL, while the hydrogen substitution (20) demonstrated IC<sub>50</sub> of 1.17 µg/mL (Figure 4) (Torres et al., 2011).

Other interesting active prototype obtained by molecular hybridization was developed by Santos and co-workers (2009) between phthalimide subunit in the thalidomide and a dapsone. This scaffold was designed to be active against <i>M. leprae</i>, but it presented interesting activity against MTB with MIC of 3.9 µg/mL (Santos et al., 2009).

**Prodrug approach**

In 1958, Albert called prodrug as “any compound that undergoes biotransformation prior to exhibit its pharmacological effects” (Albert, 1958). Lately, Haper (1959) try to improve this definition proposing the term latentiaton, which was defined as “the chemical modification of biologically active compound to form a new
An interesting study performed by Chung and co-workers (2009) and Simões and co-workers (2009) studied the influence of carriers on pyrazinamide (23 and 24), and they synthesized esters and amides compounds with higher lipophilicity than pyrazinamide. Posteriorly, the biological results have revealed that esters derivatives presented better activity against MTB than amides derivatives (Figure 6) (Simões et al., 2009).

Simões and co-workers (2009) studied the influence of carriers on pyrazinamide (23 and pyrazinamide acid (24), and they synthesized esters and amides compounds with higher lipophilicity than pyrazinamide. Posteriorly, the biological results have revealed that esters derivatives presented better activity against MTB than amides derivatives (Figure 6) (Simões et al., 2009).

An interesting study performed by Chung and co-workers (2008) about pyrazinamide carriers, led to a series of amino methylene analogs of pyrazinamide (25 and 26). They evaluated the influence of the size carbon chain size in these carriers and related these to biological activity. The authors discovered two new prototypes (25 and 26) as antitubercular drugs (Figure 7) (Chung et al., 2008).

Using the molecular hybridization, Mao and co-workers (2007) synthesized the prodrug 5-(2,8-di(trifluoromethyl)quinolin-4-yl)oxymethyl)isoxazole-3-carboxylic acid ethyl ester (29). This compound was obtained through combination between mefloquine fragment (27) and isoxazolcarboxamide (28) (Mao et al., 2007). Recently, Mao and co-workers (2011) have performed substitutions in the prototype 29 in order to

### Bioisosterism

Increase carbon chain using propyl and butyl. The compounds 30 was two times less active (IC$_{50}$ = 1.8 µM) than 29 (IC$_{50}$ = 0.9 µM), and 31 had similar activity (IC$_{50}$ = 0.9 µM) when compared prototype (Figure 8) (Mao et al., 2011).

Bioisosterism term is applied in compounds which have similar physico-chemical and biological effects. This molecular modification is based on the substitution of molecular fragments, as for example, a functional group by another which similar physico-chemical properties (Thornber, 1957). Bioisosterism was classified into two categories: classic and non-classic. Classic bioisosterism is classified through valence atoms, chemical groups and aromatic rings (Table 1) (Patini and LaVoie, 1996; Barreiro and Fraga, 2008).

A classic example of drugs obtained from bioisosterism are fluoroquinolones. These compounds are known to inhibit bacterial DNA replication and transcription. Fluoroquinolones are used mainly in patients with multidrug-resistance tuberculosis (MDR-TB). The more usual fluoroquinolones used in TB are: ciprofloxacin, sparflaxin, ofloxacin, moxifloxacin and levofloxacin (Figure 9) (Renau et al., 1996).

Linezolid is an antibacterial agent used in the treatment of pneumonia caused by gram-negative bacteria. It was evaluated against MDR showing interesting result. So, some bioisosteres were developed, as PNU-100480, radexolid and torelozid (Figure 10) (Ford et al., 2001; Pinon et al., 2010; Leach et al., 2011).

### New drugs antitubercular in clinical trial

Since the discovery of rifampicin in 60’s none new drug was introduced in the market to treat TB. Currently, some drugs are under clinical trial by several public and private partnerships (Dover and Coxon 2011).

Nowadays, pharmaceutical partnerships have contributed to TB drug development. One example is phase II clinical trial of TMC207 and PA-824 (Figure 11). TMC207, a new ATP synthase inhibitor with wide antimycobacterium spectrum, is being evaluated in clinical trials. This diarylquinoline was first synthesized by Andries et al (2005) and showed high activity against MTB resistant to isoniazid and pyrazinamide with MIC = 0.01 and 0.03 µg/mL respectively (Andries et al., 2005). PA-824, a metronidazole analogue, was discovered...
Figure 8. New prodrugs obtained by Mao and co-workers (2011).

Table 1. Bioisosters classical group and atoms

<table>
<thead>
<tr>
<th>Monovalent</th>
<th>Divalent</th>
<th>Trivalent</th>
<th>Tetravalent</th>
<th>Equivalence rings</th>
</tr>
</thead>
<tbody>
<tr>
<td>F, OH, NH2, CH3</td>
<td>-CH₂⁻</td>
<td>CH⁻</td>
<td></td>
<td>=C=</td>
</tr>
<tr>
<td>Cl, SH₂, PH₂, Si₃, SR</td>
<td>-O⁻</td>
<td>=N⁻</td>
<td>=Si⁻</td>
<td></td>
</tr>
<tr>
<td>Br</td>
<td>-S⁻</td>
<td>=P⁻</td>
<td>=N'⁻</td>
<td></td>
</tr>
<tr>
<td>I</td>
<td>-Se⁻</td>
<td>=As⁻⁻</td>
<td>=P⁺</td>
<td></td>
</tr>
<tr>
<td></td>
<td>-Te⁻</td>
<td>=Sb⁻⁻</td>
<td>=As⁺⁻</td>
<td></td>
</tr>
</tbody>
</table>

Figure 9. Fluoroquinolones obtained by bioisosterism.
as chemotherapeutic agents (Angrawal et., 1979) and currently is being evaluated in clinical trial as antitubercular drug. *In vitro* activity studies, PA-824 showed MIC value of 0.015 µg/ml without cross-resistance with current drugs (Strover et al., 2000).

Compounds as LL-3858, ethambutol analogue SQ109 (cell wall multitarget inhibitor) and mitronidazol analogue OPC-67683 (cell wall multitarget inhibitor) also began their clinical trial recently by Lupin Ltd, Otsuka Pharmaceutica and Sequella Inc respectively with interesting results (Figure 11) (Dover and Coxon, 2011).

Thioridazine, initially known as neuroleptic, has showed to be a potent antitubercular providing cure inclusive in XDR-TB patients. The trial performed in India (Mumbai) and Argentina (Buenos Aires), demonstrated cure of 80% of the XDR-TB patients evaluated. Others two interesting drugs under clinical trial are SQ609 and RS-118641 (Figure 12) (Amaral et al., 2010; Dover and Coxon, 2011).
CONCLUSION

Nowadays TB drug discovery is a challenge. Absence of efficacy, resistance, poor compliance and co-morbidities are some factors that difficult TB treatment. The molecular modification is an important and promising tool to discovery new antitubercular drugs, this fact can be perceived in the current pipeline TB drugs in clinical trial that almost of them were obtained using this strategy. Furthermore, many problems associated with efficacy, treatment time, drug resistance and adverse effects can be resolved using this strategy.

ACKNOWLEDGEMENTS

The authors is grateful to FAPESP (Função de Amparo a Pesquisas do Estado de São Paulo) and CNPQ (National Counsel of Technological and Scientific Development) to supported the studies.

REFERENCES


